Canada-based PharmaTher has received US Food and Drug Administration (FDA) approval for its ketamine therapy for surgical ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

Real-time index price for Nasdaq US Sm Cap Consumer Electronics Index (NQCE), along with buy or sell indicators, analysis, ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

For more information about PharmaTher, please contact: Fabio Chianelli Chief Executive Officer PharmaTher Holdings Ltd. Tel: 1-888-846-3171 Email: [email protected] Website: www.pharmather.com ...

--PharmaTher Holdings Ltd., a specialty psychedelic pharmaceutical company, today announced it submitted an Investigational New Drug application with the U.S. Food and Drug Administration for the ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...